Mongersen

Drug Profile

Mongersen

Alternative Names: GED-0301

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Giuliani
  • Developer Celgene Corporation
  • Class Anti-inflammatories; Antisense oligonucleotides
  • Mechanism of Action Smad7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Crohn's disease
  • Phase II Ulcerative colitis

Most Recent Events

  • 01 Dec 2016 Celgene Corporation completes a phase I pharmacokinetics trial in Ulcerative colitis (In volunteers) in United Kingdom (PO) (NCT02957474)
  • 23 Nov 2016 Celgene Corporation plans a phase III trial for Crohn's disease (In adolescents, In adults, Treatment-experienced) in USA, Canada and European Union (PO, Tablet) (NCT02974322)
  • 03 Nov 2016 Celgene Corporation plans a phase I pharmacokinetics trial in Healthy volunteers in USA and United Kingdom (PO) (NCT02957474)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top